Clin2
NCT07153289Worth exploringNot yet recruiting

CAR T cells targeting CD318 for pancreatic cancer

Carcinoma, Pancreatic DuctalPancreatic Neoplasms

Part of Cancer, Digestive system, Hormones & metabolism clinical trials.

This trial tests a new kind of immune treatment called CAR T cells that target a protein (CD318) found on some pancreatic cancer cells. It's for people with advanced pancreatic cancer whose disease has worsened after standard treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
38 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have advanced pancreatic cancer that has spread or cannot be removed
  • Your cancer has gotten worse after at least one standard treatment
  • Your tumor has a specific protein called CD318 (confirmed by a lab test)
  • You are generally active and able to take care of yourself (ECOG 0 or 1)
  • Your liver, kidneys, and blood cell counts are in good enough shape

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06885697Recruiting· Phase 1
CAR T cells targeting mesothelin for solid tumors

This study tests a new treatment called CAR T cells that target a protein called mesothelin found on certain cancer cells. The CAR T cells are made from your own immune cells and may help shrink tumors that have not responded to other therapies.

Bethesda, Maryland
NCT07066995Recruiting· Phase 1/Phase 2
Dual-target CAR-T cell therapy for advanced pancreatic cancer

This trial tests a new type of cell therapy (CAR-T) that targets two markers on pancreatic cancer cells. It's for people with advanced pancreatic cancer who have already tried standard chemotherapy.

Beijing, Beijing Municipality
NCT05620732Recruiting
CAR-T treatment for advanced stomach or pancreatic cancer

This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.

Shenzhen, Guangdong
NCT07480928Recruiting· Phase 1/Phase 2
CAR-NK cell therapy for advanced pancreatic cancer

This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.

Shenzhen, Guangdong
NCT07627711Recruiting· Phase 1/Phase 2
CAR-NK cells for advanced pancreatic cancer

This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.

Shenzhen, Guangdong
NCT07425483Recruiting· Phase 1
CAR-NK cell therapy for advanced pancreatic cancer

This trial tests a new treatment using immune cells (CAR-NK cells) to fight pancreatic cancer that has spread or come back. It may be an option if standard treatments have stopped working, were not tolerated, or were refused.

Shanghai

Hear when a new Pancreatic Neoplasms trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.